Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CNBX PHARMACEUTICALS INC.

(CNBX)
Delayed OTC Markets  -  09:30 2022-09-30 am EDT
3.200 USD   +2.98%
09/29Cnbx Peer-reviewed Study : "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate
PR
09/28CNBX Pharmaceuticals Announces New Patent Granted in Australia
PR
07/25Cnbx Pharmaceuticals Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
SummaryQuotesChartsNewsCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

CNBX Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022

07/14/2022 | 08:03am EDT

CNBX Pharmaceuticals Inc. reported earnings results for the third quarter and nine months ended May 31, 2022. For the third quarter, the company reported net loss was USD 0.681652 million compared to USD 1.32 million a year ago.
For the nine months, net loss was USD 3.24 million compared to USD 2.51 million a year ago. Basic loss per share from continuing operations was USD 2.65 compared to USD 2.21 a year ago. Diluted loss per share from continuing operations was USD 2.65 compared to USD 2.21 a year ago.


© S&P Capital IQ 2022
All news about CNBX PHARMACEUTICALS INC.
09/29Cnbx Peer-reviewed Study : "Possible Future Therapeutic Value" for CNBX Proprietary Drug C..
PR
09/28CNBX Pharmaceuticals Announces New Patent Granted in Australia
PR
07/25Cnbx Pharmaceuticals Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
07/25CNBX Pharmaceuticals Inc. Announces Executive Changes
CI
07/14CNBX PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition ..
AQ
07/14CNBX Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
05/31CNBX Pharmaceuticals Release a New Corporate Presentation
PR
05/05CNBX Pharmaceuticals Granted Patent in Hong Kong
PR
05/05CNBX Pharmaceuticals Inc. Receives Grant of Patent Notice by the Patent Registry, Intel..
CI
04/12CNBX PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition ..
AQ
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -3,19 M - -
Net cash 2021 0,51 M - -
P/E ratio 2021 -7,37x
Yield 2021 -
Capitalization 4,03 M 4,03 M -
EV / Sales 2020 3 496x
EV / Sales 2021 -
Nbr of Employees 10
Free-Float 42,4%
Chart CNBX PHARMACEUTICALS INC.
Duration : Period :
CNBX Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Eyal Barad Chief Executive Officer & Director
Gabriel Yariv Executive Chairman, President & COO
Uri Ben-Or Chief Financial Officer
Ilan Hochman Vice President-Research & Development
Sanja Goldberg Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
CNBX PHARMACEUTICALS INC.-66.03%4
GILEAD SCIENCES, INC.-15.04%77 320
VERTEX PHARMACEUTICALS31.85%74 255
REGENERON PHARMACEUTICALS, INC.9.08%73 646
BIONTECH SE-47.68%32 778
WUXI APPTEC CO., LTD.-39.54%29 044